NovoCure Limited
NVCR
$15.58
-$0.25-1.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 20.54% | 21.81% | 19.28% | 13.36% | 4.17% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.54% | 21.81% | 19.28% | 13.36% | 4.17% |
| Cost of Revenue | 2.20% | 10.22% | 1.87% | 13.58% | 12.50% |
| Gross Profit | 26.26% | 25.72% | 25.72% | 13.29% | 1.82% |
| SG&A Expenses | 47.67% | 0.08% | -4.95% | -0.09% | 8.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.07% | 0.87% | -2.52% | -2.43% | 4.68% |
| Operating Income | -38.55% | 44.90% | 46.37% | 34.46% | -6.22% |
| Income Before Tax | -43.27% | 55.24% | 57.83% | 38.05% | -18.35% |
| Income Tax Expenses | 25.41% | 611.40% | 202.96% | 259.31% | 80.08% |
| Earnings from Continuing Operations | -40.02% | 38.22% | 41.87% | 26.95% | -26.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.02% | 38.22% | 41.87% | 26.95% | -26.21% |
| EBIT | -38.55% | 44.90% | 46.37% | 34.46% | -6.22% |
| EBITDA | -39.18% | 46.55% | 48.70% | 36.25% | -6.95% |
| EPS Basic | -38.08% | 39.07% | 42.63% | 28.06% | -23.90% |
| Normalized Basic EPS | -37.87% | 55.86% | 56.25% | 42.90% | -55.44% |
| EPS Diluted | -38.10% | 39.07% | 42.61% | 28.06% | -23.90% |
| Normalized Diluted EPS | -37.87% | 55.86% | 56.25% | 42.90% | -55.44% |
| Average Basic Shares Outstanding | 1.39% | 1.38% | 1.33% | 1.51% | 1.86% |
| Average Diluted Shares Outstanding | 1.39% | 1.38% | 1.33% | 1.51% | 1.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |